Abstract
A new anticancer agent based on the conjugation of a photoactivatable Pt(IV) pro-drug to a cyclic RGD-containing peptide is described. Upon visible light irradiation, phototoxicity was induced preferentially in SK-MEL-28 melanoma cancer cells overexpressing αVβ3 integrin compared to control DU-145 human prostate carcinoma cells.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents* / chemistry
-
Antineoplastic Agents* / pharmacology
-
Antineoplastic Agents* / radiation effects
-
Cell Line, Tumor
-
Humans
-
Integrin alphaVbeta3 / metabolism*
-
Light
-
Organoplatinum Compounds* / chemistry
-
Organoplatinum Compounds* / pharmacology
-
Organoplatinum Compounds* / radiation effects
-
Peptides, Cyclic* / chemistry
-
Peptides, Cyclic* / pharmacology
-
Peptides, Cyclic* / radiation effects
-
Platinum / metabolism
-
Prodrugs* / chemistry
-
Prodrugs* / pharmacology
-
Prodrugs* / radiation effects
-
Receptors, Vitronectin / metabolism
Substances
-
Antineoplastic Agents
-
Integrin alphaVbeta3
-
Organoplatinum Compounds
-
Peptides, Cyclic
-
Prodrugs
-
Receptors, Vitronectin
-
integrin alphaVbeta5
-
Platinum